Skip to main content

Pfizer’s Sayana® Press Becomes First Injectable Contraceptive In The United Kingdom Available For Administration By Self-Injection

Pfizer Inc. announced that the company’s injectable contraceptive, Sayana®Press (medroxyprogesterone acetate), is now available to women in the United Kingdom (UK) for administration by self-injection. This follows the recent approval from the UK Medicines and Healthcare Products Regulatory Agency (MHRA) of an update to the Sayana® Press label, adding the option for self-injection by women when considered appropriate by a healthcare professional (HCP).

Institutional Author(s): Pfizer, Inc.
Publication date: September, 2015

  • Brief Link to Press Release